blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3089749

EP3089749 - COMBINED PREPARATIONS FOR THE TREATMENT OF CANCER [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  27.03.2020
Database last updated on 11.04.2026
FormerThe patent has been granted
Status updated on  19.04.2019
FormerGrant of patent is intended
Status updated on  13.04.2019
FormerExamination is in progress
Status updated on  01.03.2019
FormerGrant of patent is intended
Status updated on  25.02.2019
FormerExamination is in progress
Status updated on  28.01.2019
FormerGrant of patent is intended
Status updated on  24.09.2018
FormerExamination is in progress
Status updated on  16.03.2018
Most recent event   Tooltip01.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 03.08.2022  [2022/31]
Applicant(s)For all designated states
Immutep S.A.S.
Parc Club Orsay
2 rue Jean Rostand
91400 Orsay / FR
[2019/14]
Former [2016/45]For all designated states
Immutep S.A.S.
Parc Club Orsay
2 Rue Jean Rostand
91400 Orsay / FR
Inventor(s)01 / TRIEBEL, Frédéric
10, rue Saint-Louis
F-78000 Versailles / FR
 [2019/21]
Former [2016/45]01 / TRIEBEL, Frédéric
10 rue Saint-Louis
F-78000 Versailles / FR
Representative(s)Thornton, Neil
Reddie & Grose LLP The White Chapel Building
10 Whitechapel High Street
London E1 8QS / GB
[2019/21]
Former [2016/45]Thornton, Neil
Reddie & Grose LLP
16 Theobalds Road
London
WC1X 8PL / GB
Application number, filing date14830806.719.12.2014
[2016/45]
WO2014EP78779
Priority number, dateGB2013002262619.12.2013         Original published format: GB 201322626
[2016/45]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015091970
Date:25.06.2015
Language:EN
[2015/25]
Type: A1 Application with search report 
No.:EP3089749
Date:09.11.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 25.06.2015 takes the place of the publication of the European patent application.
[2016/45]
Type: B1 Patent specification 
No.:EP3089749
Date:22.05.2019
Language:EN
[2019/21]
Search report(s)International search report - published on:EP25.06.2015
ClassificationIPC:A61K31/47, A61K31/282, A61K38/16, C07K14/705, A61P35/00
[2016/45]
CPC:
A61K38/1774 (EP,KR,US); A61K31/282 (US); A61K31/4745 (EP,KR,US);
A61K31/555 (EP,KR,US); A61K45/06 (EP,KR,US); A61P35/00 (EP,KR);
A61P43/00 (EP); C07K14/70503 (EP,KR,US); A61K2300/00 (KR);
C07K2319/30 (EP,KR,US) (-)
C-Set:
A61K31/4745, A61K2300/00 (US,EP);
A61K31/555, A61K2300/00 (EP,US);
A61K38/1774, A61K2300/00 (US,EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/45]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:KOMBINATIONSPRÄPARATE ZUR BEHANDLUNG VON KREBS[2016/45]
English:COMBINED PREPARATIONS FOR THE TREATMENT OF CANCER[2016/45]
French:PRÉPARATIONS COMBINÉES POUR LE TRAITEMENT DU CANCER[2016/45]
Entry into regional phase19.07.2016National basic fee paid 
19.07.2016Designation fee(s) paid 
19.07.2016Examination fee paid 
Examination procedure19.07.2016Examination requested  [2016/45]
19.04.2017Amendment by applicant (claims and/or description)
20.03.2018Despatch of a communication from the examining division (Time limit: M04)
30.07.2018Reply to a communication from the examining division
25.09.2018Communication of intention to grant the patent
25.01.2019Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
25.01.2019Fee for grant paid
25.01.2019Fee for publishing/printing paid
25.02.2019Communication of intention to grant the patent
25.02.2019Receipt of the translation of the claim(s)
27.02.2019Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
12.04.2019Information about intention to grant a patent
12.04.2019Receipt of the translation of the claim(s)
Divisional application(s)EP19158672.6  / EP3511004
EP24178618.5
Opposition(s)25.02.2020No opposition filed within time limit [2020/18]
Fees paidRenewal fee
11.10.2016Renewal fee patent year 03
12.12.2017Renewal fee patent year 04
12.12.2018Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU19.12.2014
AL22.05.2019
CY22.05.2019
CZ22.05.2019
EE22.05.2019
HR22.05.2019
LT22.05.2019
LV22.05.2019
MC22.05.2019
MK22.05.2019
MT22.05.2019
RO22.05.2019
RS22.05.2019
SI22.05.2019
SK22.05.2019
SM22.05.2019
BG22.08.2019
IS22.09.2019
[2022/31]
Former [2021/34]HU19.12.2014
AL22.05.2019
CY22.05.2019
CZ22.05.2019
EE22.05.2019
HR22.05.2019
LT22.05.2019
LV22.05.2019
MC22.05.2019
MT22.05.2019
RO22.05.2019
RS22.05.2019
SI22.05.2019
SK22.05.2019
SM22.05.2019
BG22.08.2019
IS22.09.2019
Former [2021/32]HU19.12.2014
AL22.05.2019
CY22.05.2019
CZ22.05.2019
EE22.05.2019
HR22.05.2019
LT22.05.2019
LV22.05.2019
MC22.05.2019
RO22.05.2019
RS22.05.2019
SI22.05.2019
SK22.05.2019
SM22.05.2019
BG22.08.2019
IS22.09.2019
Former [2021/31]AL22.05.2019
CY22.05.2019
CZ22.05.2019
EE22.05.2019
HR22.05.2019
LT22.05.2019
LV22.05.2019
MC22.05.2019
RO22.05.2019
RS22.05.2019
SI22.05.2019
SK22.05.2019
SM22.05.2019
BG22.08.2019
IS22.09.2019
Former [2021/26]AL22.05.2019
CY22.05.2019
CZ22.05.2019
EE22.05.2019
HR22.05.2019
LT22.05.2019
LV22.05.2019
MC22.05.2019
RO22.05.2019
RS22.05.2019
SI22.05.2019
SK22.05.2019
SM22.05.2019
BG22.08.2019
Former [2020/39]AL22.05.2019
CZ22.05.2019
EE22.05.2019
HR22.05.2019
LT22.05.2019
LV22.05.2019
MC22.05.2019
RO22.05.2019
RS22.05.2019
SI22.05.2019
SK22.05.2019
SM22.05.2019
BG22.08.2019
Former [2020/26]AL22.05.2019
CZ22.05.2019
EE22.05.2019
HR22.05.2019
LT22.05.2019
LV22.05.2019
RO22.05.2019
RS22.05.2019
SI22.05.2019
SK22.05.2019
SM22.05.2019
BG22.08.2019
Former [2020/14]AL22.05.2019
CZ22.05.2019
EE22.05.2019
HR22.05.2019
LT22.05.2019
LV22.05.2019
RO22.05.2019
RS22.05.2019
SK22.05.2019
SM22.05.2019
BG22.08.2019
Former [2020/11]AL22.05.2019
CZ22.05.2019
EE22.05.2019
HR22.05.2019
LT22.05.2019
LV22.05.2019
RO22.05.2019
RS22.05.2019
SK22.05.2019
BG22.08.2019
Former [2020/10]AL22.05.2019
CZ22.05.2019
HR22.05.2019
LT22.05.2019
LV22.05.2019
RO22.05.2019
RS22.05.2019
BG22.08.2019
Former [2020/09]AL22.05.2019
CZ22.05.2019
HR22.05.2019
LT22.05.2019
LV22.05.2019
RS22.05.2019
BG22.08.2019
Former [2019/52]AL22.05.2019
HR22.05.2019
LT22.05.2019
LV22.05.2019
RS22.05.2019
BG22.08.2019
Former [2019/50]AL22.05.2019
HR22.05.2019
LT22.05.2019
LV22.05.2019
RS22.05.2019
Former [2019/47]LT22.05.2019
Cited inInternational search[Y] WO2009044273  (IMMUTEP et al.) [Y] 1-29 * abstract * * page 6 - page 7 * * claims 1,3,5 *
 [Y] WO2009032256  (CELL GENESYS INC et al.) [Y] 1-29 * abstract * * claims 1,2 *
 [Y]   BRIGNONE CHRYSTELLE ET AL: "First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity", JOURNAL OF TRANSLATIONAL MEDICINE, BIOMED CENTRAL, LONDON, GB, vol. 8, no. 1, 23 July 2010 (2010-07-23), pages 71, XP021078895, ISSN: 1479-5876, DOI: 10.1186/1479-5876-8-71 [Y] 1-29 * the whole document *

DOI:   http://dx.doi.org/10.1186/1479-5876-8-71
 [Y]   FOUGERAY S ET AL: "A soluble LAG-3 protein as an immunopotentiator for therapeutic vaccines: Preclinical evaluation of IMP321", VACCINE, ELSEVIER LTD, GB, vol. 24, no. 26, 29 June 2006 (2006-06-29), pages 5426 - 5433, XP028011133, ISSN: 0264-410X, [retrieved on 20060629], DOI: 10.1016/J.VACCINE.2006.03.050 [Y] 1-29 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.vaccine.2006.03.050
 [A]   ANNA K NOWAK ET AL: "Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 63, no. 15, 1 August 2003 (2003-08-01), pages 4490 - 4496, XP008156419, ISSN: 0008-5472, [retrieved on 20030807] [A] 1-29 * the whole document *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.